Monte Rosa Therapeutics (GLUE) Price & Analysis

Compare

299 Followers

GLUE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.50 - $12.40

Previous CloseN/A

Volume283.19K

Average Volume (3M)430.26K

Market Cap

$351.22M

Enterprise Value$285.03M

Total Cash (Recent Filing)$326.07M

Total Debt (Recent Filing)$41.86M

Price to Earnings (P/E)84.4

Beta1.93

Next Earnings

Aug 07, 2025

EPS Estimate

-0.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.57

Shares Outstanding61,509,823

10 Day Avg. Volume463,762

30 Day Avg. Volume430,259

Financial Highlights & Ratios

PEG Ratio0.65

Price to Book (P/B)1.55

Price to Sales (P/S)0.00

P/FCF Ratio10.48

Enterprise Value/Market Cap0.81

Enterprise Value/Revenue1.04

Enterprise Value/Gross Profit1.83

Enterprise Value/Ebitda-0.89

Forecast

1Y Price Target

$18.50

Price Target Upside226.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Monte Rosa Therapeutics News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical TrialsMRT-2359 has shown encouraging activity in heavily pretreated CRPC patients previously exposed to androgen receptor targeted agents.

Financial PerformanceGLUE reported Q1 net income of $47MM and cash of $331MM (runway into 2028).

PartnershipsMonte Rosa's lead I&I asset, MRT-6160, is advancing toward multiple Phase 2 trials, supported through a partnership with Novartis.

Bears Say

Clinical Data NeedsThere is a need for additional clinical data to inform views on MRT-2359's potential indications in MYC-expressing tumors, as the focus narrows to CRPC and HR+ breast cancer.

Market SentimentShort Interest is 17.5% of the float.

Revenue ForecastIt's currently challenging to forecast the precise development paths and subsequent potential revenues for the assets.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

22.88% Insiders

20.32% Mutual Funds

0.02% Other Institutional Investors

46.88% Public Companies and

Individual Investors

Detailed Ownership Overview >

GLUE FAQ

What was Monte Rosa Therapeutics’s price range in the past 12 months?

Monte Rosa Therapeutics lowest stock price was $3.50 and its highest was $12.40 in the past 12 months.

What is Monte Rosa Therapeutics’s market cap?

Monte Rosa Therapeutics’s market cap is $351.22M.

When is Monte Rosa Therapeutics’s upcoming earnings report date?

Monte Rosa Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 11 days.

How were Monte Rosa Therapeutics’s earnings last quarter?

Monte Rosa Therapeutics released its earnings results on May 08, 2025. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of -$0.003 by $0.573.

Is Monte Rosa Therapeutics overvalued?

According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Monte Rosa Therapeutics pay dividends?

Monte Rosa Therapeutics does not currently pay dividends.

What is Monte Rosa Therapeutics’s EPS estimate?

Monte Rosa Therapeutics’s EPS estimate is -0.38.

How many shares outstanding does Monte Rosa Therapeutics have?

Monte Rosa Therapeutics has 61,509,823 shares outstanding.

What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?

Monte Rosa Therapeutics reported an EPS of $0.57 in its last earnings report, beating expectations of -$0.003. Following the earnings report the stock price went up 9.61%.

Which hedge fund is a major shareholder of Monte Rosa Therapeutics?

Currently, no hedge funds are holding shares in GLUE

Monte Rosa Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

2.88%

Trailing 12-Months

Asset Growth

47.41%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on the discovery and development of novel small molecules that harness the body's natural mechanisms to selectively degrade disease-causing proteins. The company operates within the pharmaceutical and biotechnology sectors, with a primary emphasis on advancing therapies for cancer and other serious diseases through its proprietary drug discovery platform.

GLUE Company Deck

GLUE Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in clinical trials and strategic partnerships, particularly with the success of MRT-6160 and strategic agreement with Novartis. However, challenges such as lower than expected biomarker positivity in certain cancer cohorts and strategic shifts were noted. Overall, the positive developments and financial strength suggest a strong position for future growth.Read More>

GLUE Stock 12 Month Forecast

Average Price Target

$18.50

▲(226.28%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","12":"$12","21":"$21","7.5":"$7.5","16.5":"$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7.5,12,16.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.61,5.793846153846154,6.977692307692308,8.161538461538463,9.345384615384617,10.529230769230772,11.713076923076924,12.896923076923077,14.080769230769231,15.264615384615386,16.44846153846154,17.632307692307695,18.81615384615385,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.61,5.678461538461539,6.7469230769230775,7.815384615384616,8.883846153846154,9.952307692307693,11.020769230769233,12.08923076923077,13.157692307692308,14.226153846153846,15.294615384615387,16.363076923076925,17.431538461538462,{"y":18.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.61,5.563076923076924,6.516153846153847,7.469230769230769,8.422307692307694,9.375384615384615,10.32846153846154,11.281538461538464,12.234615384615385,13.18769230769231,14.14076923076923,15.093846153846155,16.04692307692308,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.3,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.94,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >